REGENERON PHARMACEUTICALS, INC.
At today's price, REGENERON PHARMACEUTICALS, INC. (REGN) is priced for +8.8% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
At $610.05 (as of June 27, 2026), Regeneron is supported by asset-based, relative-multiple, and growth-DCF value, with the methods describing a value-and-asset name rather than a pure growth bet. The implied growth baked into the price is a modest 6 percent, low for a company whose two biggest drugs are still expanding. The near-term debate is the Eylea franchise. Combined U.S. Eylea sales fell 10 percent under biosimilar and competitive pressure, even as the new Eylea HD formulation grew 52 pe
Is REGN overvalued? See what's priced in →
1,355 institutional managers reported holding REGN in 13F filings for the quarter ended 2026-03-31. Together they hold about 78% of the company; the top 10 hold 38%. 108 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 3.3M shares were sold short as of the 2026-06-15 count, about 3% of shares outstanding (3.4 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
REGN has cut its share count 1% over the past five years, spending $12.20B on repurchases. It pays a dividend, and has for 1 year running. Cash returned over the past three years: $468.10M in dividends and $7.68B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at REGN over the trailing three years. Absence is a fact about the company, not a signal. 20 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
REGN's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-04 | +4.7% | +9.2% |
| 2023-11-03 | +3.2% | +11.8% |
| 2024-02-06 | -1.3% | +0.7% |
| 2024-05-03 | +5.9% | +8.1% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
REGN's latest 8-K filings: 2026-07-06 (items 2.02); 2026-06-17 (items 5.07); 2026-04-29 (items 2.02, 9.01); 2026-04-08 (items 2.02); 2026-01-30 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: July 3, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.